18119-24-9

Basic information

• Product Name: 6-CHLORO-8-HYDROXYQUINOLINE
• Synonyms: 6-CHLORO-8-HYDROXYQUINOLINE;8-chloroquinolin-6-ol;8-Chloro-6-hydroxyquinoline;6-Quinolinol, 8-chloro-
• CAS NO: 18119-24-9
• Molecular Formula: C9H6ClNO
• Molecular Weight: 179.60304
• Mol File: 18119-24-9.mol

Chemical Properties

• Melting Point: 237-238 °C (decomp)(Solv: ethanol (64-17-5))
• Boiling Point: 343.5±22.0 °C(Predicted)
• Appearance: /
• Density: 1.412±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 8.11±0.40(Predicted)
• CAS DataBase Reference: 6-CHLORO-8-HYDROXYQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-8-HYDROXYQUINOLINE(18119-24-9)
• EPA Substance Registry System: 6-CHLORO-8-HYDROXYQUINOLINE(18119-24-9)

Safety Data

• Hazardous Substances Data: 18119-24-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-8-hydroxyquinoline is used as an intermediate in the synthesis of various pharmaceuticals for its versatile chemical properties and potential therapeutic applications.
Used in Dye Industry:
6-CHLORO-8-HYDROXYQUINOLINE is utilized as an intermediate in the production of dyes, contributing to the development of colorants for various applications.
Used in Antiseptic and Disinfectant Products:
6-Chloro-8-hydroxyquinoline is used as an active ingredient in antiseptic and disinfectant products due to its antimicrobial properties, helping to prevent and control the spread of infections.
Used in Cancer Treatment Research:
6-CHLORO-8-HYDROXYQUINOLINE is being researched for its potential therapeutic applications in the treatment of cancer, as it may exhibit antitumor effects and could be a promising candidate for further development in oncology.
Used in Microbial Infection Treatment Research:
6-Chloro-8-hydroxyquinoline is also being investigated for its potential in treating various microbial infections, given its antimicrobial properties, which could lead to new treatment options for infectious diseases.

Upstream product

• 796851-15-5 8-chloro-6-methoxyquinoline 
• 17609-80-2 4-amino-3-chlorophenol 
• 56-81-5 glycerol 
• 52671-64-4 4-Amino-3-chlorophenol hydrochloride 
• 98-95-3 nitrobenzene 

Downstream Products

• 796851-15-5 8-chloro-6-methoxyquinoline 
• 282547-38-0 6-methoxy-8-piperazinoquinoline 

Relevant articles and documents

The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists

As part of an effort to identify 5-HT1A antagonists that did not possess typical arylalkylamine or keto/amido-alkyl aryl piperazine scaffolds, prototype compound 10a was identified from earlier work in a combined 5-HT 1A antagonist/SSRI program. This quinolyl-piperazinyl piperidine analogue displayed potent, selective 5-HT1A antagonism but suffered from poor oxidative metabolic stability, resulting in low exposure following oral administration. SAR studies, driven primarily by in vitro liver microsomal stability assessment, identified compound 10b, which displayed improved oral bioavailability and lower intrinsic clearance. Further changes to the scaffold (e.g., 10r) resulted in a loss in potency. Compound 10b displayed cognitive enhancing effects in a number of animal models of learning and memory, enhanced the antidepressant-like effects of the SSRI fluoxetine, and reversed the sexual dysfunction induced by chronic fluoxetine treatment.

BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE

Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed.

6-Methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts

The present invention relates to hydrochloric acid salt and crystalline forms of the 5-HT1A binding agent 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline, as well as pharmaceutical compositions thereof, and methods of use thereof.

Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor

The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction.

CRYSTALLINE FORMS OF 6-METHOXY-8-[4-(1-(5-FLUORO)-QUINOLIN-8-YL-PIPERIDIN-4-YL)-PIPERAZIN-1-YL]-QUINOLINE

The present invention relates to crystalline forms of the 5-HT1A binding agent 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline, as well as pharmaceutical compositions thereof, and methods of use thereof.

BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE

Benzofuranyl-and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed.